The U.S. Food and Drug Administration (FDA) has issued a recall for a pharmaceutical product after identifying deviations from current Good Manufacturing Practices (CGMP). The recall underscores the agency's focus on ensuring manufacturing compliance and product safety.
Actualizaciones regulatorias24 ago 2026•1 min de lectura
FDA Recalls Product Due to CGMP Deviations
The FDA has initiated a recall of a product because of deviations from current Good Manufacturing Practices (CGMP).
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración